Retinal Vein Occlusion News and Research

RSS
Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back of the eye. Occurring mostly in the elderly or middle-aged, it causes a subacute loss of vision.
EC approves Regeneron’s EYLEA for treatment of wet AMD

EC approves Regeneron’s EYLEA for treatment of wet AMD

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Lucentis receives FDA approval for treatment of diabetic macular edema

Lucentis receives FDA approval for treatment of diabetic macular edema

Regeneron reports total revenues of $304 million for second quarter 2012

Regeneron reports total revenues of $304 million for second quarter 2012

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron reports total revenues of $123.0M for fourth quarter 2011

ForSight VISION4 to receive first milestone payment for Lucentis drug delivery device

ForSight VISION4 to receive first milestone payment for Lucentis drug delivery device

Clearside Biomedical receives $4M venture capital investment

Clearside Biomedical receives $4M venture capital investment

IRIDEX announces data from MicroPulse laser therapy study on DME

IRIDEX announces data from MicroPulse laser therapy study on DME

Lucentis receives Health Canada approval for treatment of retinal vein occlusion

Lucentis receives Health Canada approval for treatment of retinal vein occlusion

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

PDL revises revenue guidance for second quarter 2011 to $122M

PDL revises revenue guidance for second quarter 2011 to $122M

Bayer HealthCare seeks EU marketing authorization of VEGF Trap-Eye for treatment of wet AMD

Bayer HealthCare seeks EU marketing authorization of VEGF Trap-Eye for treatment of wet AMD

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Phase III RISE study of Lucentis for DME meets primary endpoint

Phase III RISE study of Lucentis for DME meets primary endpoint

Positive top-line results from VEGF Trap-Eye Phase 3 studies in macular edema due to CRVO

Positive top-line results from VEGF Trap-Eye Phase 3 studies in macular edema due to CRVO

Allergan third quarter diluted loss per share increases to $2.21

Allergan third quarter diluted loss per share increases to $2.21

FDA approves OZURDEX implant for uveitis treatment

FDA approves OZURDEX implant for uveitis treatment

PDL BioPharma reports revenue guidance of $86 million for 2010 third quarter

PDL BioPharma reports revenue guidance of $86 million for 2010 third quarter